You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 10,945,950


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,945,950
Title:Liquid inhalation formulation comprising RPL554
Abstract:The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment of the human or animal body.
Inventor(s):Spargo Peter Lionel, French Edward James, Haywood Phillip A.
Assignee:VERONA PHARMA PLC
Application Number:US15927517
Patent Claims: 1. A liquid pharmaceutical composition suitable for administration by inhalation comprising a diluent and a suspension of particles of 9 ,10-dimethoxy-2-(2 ,4 ,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3 ,4 ,6 ,7-tetrahydro-2H-pyrimido[6 ,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof ,wherein the composition comprises a phosphate buffer at a concentration of less than about 5 mg/mL;wherein the particles of RPL554 have a particle size distribution with a Dv50 (median particle size by volume) value of from about 0.2 μm to about 5 μm,wherein the concentration of particles of RPL554 in the liquid pharmaceutical composition is from about 0.1 mg/mL to about 6 mg/mL.2. A liquid pharmaceutical composition according to claim 1 , wherein the composition does not comprise a phosphate buffer.3. A liquid pharmaceutical composition according to claim 2 , wherein the composition does not comprise a buffer.4. A liquid pharmaceutical composition according to claim 1 , wherein the particles of RPL554 have a particle size distribution with a Dv50 value of from about 0.7 μm to about 2.5 μm.5. A liquid pharmaceutical composition according to claim 1 , wherein the composition further comprises one or more surfactants.6. A liquid pharmaceutical composition according to claim 5 , wherein the one or more surfactants are selected from one or more non-ionic surfactants.7. A liquid pharmaceutical composition according to claim 5 , wherein the one or more surfactants are selected from polyoxyethylene glycol sorbitan alkyl esters and sorbitan alkyl esters.8. A liquid pharmaceutical composition according to claim 1 , wherein the composition further comprises a tonicity adjuster.9. A liquid pharmaceutical composition according to claim 1 , wherein the tonicity adjuster is sodium chloride.10. A liquid pharmaceutical composition according to claim 1 , wherein the diluent is water.11. A liquid pharmaceutical composition according to claim 1 , wherein composition is suitable for administration by nebulizer.12. A nebulizer comprising a composition according to .

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.